As shown in Table 5, of the 218 patients who received anti-PD-1 monotherapy or combination therapy, 34 (15.6%) developed hepatitis (16 had grade 1, 15 had grade 2, 2 had grade 3 and 1 had grade 4). This evidence concerns the gene PDCD1 and Hepatitis.